Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder
characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial
aims at the evaluation of the efficacy and safety of the neurokinin type 2 receptor
antagonist Ibodutant in improving IBS-D symptoms.